Ocular Therapeutix (OCUL) Misses Q1 EPS by 4c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Ocular Therapeutix (OCUL) Reports First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for Treatment of Dry Eye Disease
May 12, 2020 7:13 AM EDTOcular Therapeutix, Inc. (NASDAQ: OCUL) today announced that it has dosed the first patients in its Phase 1 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED).
We are pleased to be advancing OTX-CSI in the chronic treatment of dry eye disease, said Michael Goldstein, MD, MBA, Chief Medical Officer. We believe that the intracanalicular route of administration could provide key benefits in all ocular surface diseases but particularly in dry eye. The intracanalicular route allows for preservative-free delivery of a constant dose of cyclosporine, so it may be... More
